Last reviewed 2026-05-14 · How we verify

Drug is Temozolomide Capsule.

At a glance

Approved indications

No approved indications tracked.

Common side effects

• FATIGUE
• ALOPECIA
• CONSTIPATION
• NAUSEA
• HEADACHE
• LYMPHOPENIA
• THROMBOCYTOPENIA
• DECREASED APPETITE
• NEUTROPENIA
• ALANINE AMINOTRANSFERASE INCREASED
• VOMITING
• ASPARTATE AMINOTRANSFERASE INCREASED

Key clinical trials

• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis (PHASE1, PHASE2)
• Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL (PHASE1)
• 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (PHASE2)
• A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma (PHASE1)
• A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (PHASE2, PHASE3)
• Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease (PHASE2)
• Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion (PHASE2)
• Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Drug is Temozolomide Capsule. CI brief — competitive landscape report
• Drug is Temozolomide Capsule. updates RSS · CI watch RSS
• Zhejiang Cancer Hospital portfolio CI